Bharat Immunologicals & Biologicals (BOM:524663) Cyclically Adjusted Revenue per Share: ₹0.00 (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524663 Bharat Immunologicals & Biologicals Corp Ltd BOM:524663
4 GF Score
Price ₹15.86
View Full Analysis

What is Bharat Immunologicals & Biologicals Cyclically Adjusted Revenue per Share?

Bharat Immunologicals & Biologicals BOM:524663 -0.63% 4 Cyclically Adjusted Revenue per Share is ₹0.00 as of Sep. 2023. GuruFocus rates BOM:524663 with a GF Score™ of 4/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bharat Immunologicals & Biologicals's adjusted revenue per share for the three months ended in Sep. 2023 was ₹0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹0.00 for the trailing ten years ended in Sep. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-29), Bharat Immunologicals & Biologicals's current stock price is ₹15.86. Bharat Immunologicals & Biologicals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was ₹0.00. Bharat Immunologicals & Biologicals's Cyclically Adjusted PS Ratio of today is .


Bharat Immunologicals & Biologicals  (BOM:524663) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bharat Immunologicals & Biologicals Cyclically Adjusted Revenue per Share Related Terms


Bharat Immunologicals & Biologicals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bharat Immunologicals & Biologicals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bharat Immunologicals & Biologicals Cyclically Adjusted Revenue per Share Chart

Bharat Immunologicals & Biologicals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 35.79 36.59 33.60

Bharat Immunologicals & Biologicals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.59 0.00 33.60 0.00 0.00

BOM:524663 vs VRTX, REGN, SGEN: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Bharat Immunologicals & Biologicals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bharat Immunologicals & Biologicals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bharat Immunologicals & Biologicals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bharat Immunologicals & Biologicals's Cyclically Adjusted PS Ratio falls into.


BOM:524663
4GF Score
Bharat Immunologicals & Biologicals Corp Ltd BOM:524663
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bharat Immunologicals & Biologicals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bharat Immunologicals & Biologicals's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0/151.4920*151.4920
=0.000

Current CPI (Sep. 2023) = 151.4920.

Bharat Immunologicals & Biologicals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 13.518 91.425 22.399
201403 23.869 91.425 39.551
201406 7.850 94.103 12.637
201409 5.636 96.780 8.822
201412 14.799 96.780 23.165
201503 5.397 97.163 8.415
201506 3.844 99.841 5.833
201509 3.088 101.753 4.597
201512 9.106 102.901 13.406
201603 13.700 102.518 20.245
201606 6.507 105.961 9.303
201609 2.561 105.961 3.661
201612 5.539 105.196 7.977
201703 23.361 105.196 33.642
201706 0.782 107.109 1.106
201709 1.221 109.021 1.697
201712 1.076 109.404 1.490
201803 4.946 109.786 6.825
201806 0.020 111.317 0.027
201809 1.082 115.142 1.424
201812 1.918 115.142 2.524
201903 16.208 118.202 20.773
201906 1.620 120.880 2.030
201909 1.832 123.175 2.253
201912 6.545 126.235 7.854
202003 5.385 124.705 6.542
202006 4.395 127.000 5.243
202009 5.903 130.118 6.873
202012 5.852 130.889 6.773
202103 3.589 131.771 4.126
202106 3.321 134.084 3.752
202109 5.726 135.847 6.385
202112 4.233 138.161 4.641
202203 4.834 138.822 5.275
202206 2.433 142.347 2.589
202209 6.098 144.661 6.386
202212 0.000 145.763 0.000
202303 1.772 146.865 1.828
202306 0.000 150.280 0.000
202309 0.000 151.492 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹0.00 mean?
Bharat Immunologicals & Biologicals (BOM:524663) has a Cyclically Adjusted Revenue per Share of ₹0.00 as of Sep. 2023. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bharat Immunologicals & Biologicals and its competitors.
Is Bharat Immunologicals & Biologicals' Cyclically Adjusted Revenue per Share too high?
Bharat Immunologicals & Biologicals' current Cyclically Adjusted Revenue per Share is ₹0.00. Overall, Bharat Immunologicals & Biologicals has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Bharat Immunologicals & Biologicals' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Bharat Immunologicals & Biologicals' Cyclically Adjusted Revenue per Share of ₹0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bharat Immunologicals & Biologicals and its competitors. Bharat Immunologicals & Biologicals's current Cyclically Adjusted Revenue per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bharat Immunologicals & Biologicals stock overvalued right now?
Bharat Immunologicals & Biologicals (BOM:524663) has a current Cyclically Adjusted Revenue per Share of ₹0.00. The current Cyclically Adjusted Revenue per Share is ₹0.00. Bharat Immunologicals & Biologicals' overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bharat Immunologicals & Biologicals (BOM:524663), the current Cyclically Adjusted Revenue per Share is ₹0.00 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bharat Immunologicals & Biologicals Business Description

Address Village Chola, BIBCOL, OPV Plant, Bulandshahar, UP, IND, 203203
Bharat Immunologicals & Biologicals Corp Ltd is an India-based biotechnology company. It primarily manufactures Oral polio vaccines. In addition, the company also manufactures zinc tablets, diarrhea management kits, and Ready to Use Therapeutic Food (RUTF). It also manufactures nutraceuticals and biological products for the treatment of health deficiencies and disorders. The firm is organized into three segments: Oral Polio Vaccine, Zinc Tablets, and BIB VIT, BIBSANIT. The group principally operates in India and generates the majority of its revenue from sales of Oral polio vaccines.
4GF Score

Get the complete analysis for BOM:524663

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹15.86
Price